AI-Driven Drug Discovery Deals Accelerate
Key Questions
What major pharma-AI partnerships were recently announced?
Pfizer licensed Chai Discovery's platform, Alnylam entered a $2B deal with Inceptive, and Waypoint Bio raised $20M for CAR T therapies. Lucera was also launched as part of the expanding ecosystem.
What did SLAS 2026 highlight about AI in drug discovery?
The conference emphasized a shift toward orchestration and data quality in AI-driven pharma R&D. This validates AI as a central component, creating investment and career opportunities while noting ongoing challenges like protein dynamics blind spots.
How is physical AI entering drug discovery processes?
Experts like Woody Sherman discuss the integration of physical AI for more accurate modeling in drug discovery. This builds on partnerships that combine AI platforms with traditional pharma expertise.
What integrations support scientific reasoning in AI drug discovery?
Causaly and Microsoft are integrating scientific reasoning and analytics tools to enhance drug discovery platforms. These efforts address the need for better data handling and predictive capabilities.
What challenges remain in AI for pharma according to recent studies?
A study on PKMYT1 revealed AI blind spots in protein dynamics, underscoring the need for improved models. Despite rapid deals, these limitations highlight ongoing R&D hurdles in the field.
Major pharma-AI partnerships: Pfizer licensing Chai Discovery's platform, Alnylam $2B deal with Inceptive (now named), Waypoint Bio $20M for CAR T, Lucera launched. SLAS 2026 highlights shift to orchestration and data quality. This validates AI as central to pharma R&D, creating investment and career opportunities. Note: a recent study on PKMYT1 reveals AI blind spots in protein dynamics, highlighting ongoing challenges.